Skip to main content
      Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatolog

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatologists may feel this is too stringent and use a higher ASDAS value for treatment intensification #EULAR2024 Abstract 0060 @RheumNow https://t.co/54vZUz7IEz
      Nice idea from Erlangen: B cell then T cell suppression for ACPA+ RA. A tolergenic reset of sorts. Sounds interesting…

      David Liew drdavidliew

      3 months 2 weeks ago
      Nice idea from Erlangen: B cell then T cell suppression for ACPA+ RA. A tolergenic reset of sorts. Sounds interesting… small study, but sadly no difference over ritux only. Does seem broadly safe though - maybe will be a strategy for another disease! #EULAR2024 OP0069 @RheumNow https://t.co/mXUS4kpRCK
      In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill s

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/wMasGSZj2o
      OP0053 #EULAR2024 @RheumNow #EULARBest
      Effect of #RTX in preclinical #RheumatoidArthritis

      RA-risk pts given 1 dose PBO

      Mrinalini Dey DrMiniDey

      3 months 2 weeks ago
      OP0053 #EULAR2024 @RheumNow #EULARBest Effect of #RTX in preclinical #RheumatoidArthritis RA-risk pts given 1 dose PBO or 1000mg RTX RTX in RA-risk pts delayed onset of RA by 1yr; no benefit on QoL Pts developing RA: RTX didn't alter PROs or disease severity when developing RA
      Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
      data now out to 60w
      good humoral and cellular response in most

      David Liew drdavidliew

      3 months 2 weeks ago
      Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020 @RheumNow https://t.co/FqVCCwUJOg
      A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb
      Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased pree

      Bella Mehta bella_mehta

      3 months 2 weeks ago
      Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased preeclampsia when they have LN #EULAR2024 Abst#0986 @RheumNow
      AMPLIFIED study:
      abatacept vs adalimumab in RF+ACPA+ early RA

      Not a single blink of difference.
      Maybe for high CCP titr

      David Liew drdavidliew

      3 months 2 weeks ago
      AMPLIFIED study: abatacept vs adalimumab in RF+ACPA+ early RA Not a single blink of difference. Maybe for high CCP titre but the inverse for low CCP. Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007 @RheumNow https://t.co/IswCub9lLn
      Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and

      Bella Mehta bella_mehta

      3 months 2 weeks ago
      Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and #humanintellegence #EULAR2024 @Lupusreference @RheumNow https://t.co/1aN8QPgVWn
      Treat to target in #lupus - difficult for many reasons.
      Also may be too much of a restrictive strategy.
      @Lupusreferenc

      Bella Mehta bella_mehta

      3 months 2 weeks ago
      Treat to target in #lupus - difficult for many reasons. Also may be too much of a restrictive strategy. @Lupusreference talks about DORIS definition of remission- however mentions may be difficult to do in daily practice #EULAR2024 @rheumnow https://t.co/XqiubfOz2n
      Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session.
      Measure Hydroxychloroquine levels! @RheumNow

      Bella Mehta bella_mehta

      3 months 2 weeks ago
      Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session. Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5
      Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will

      Bella Mehta bella_mehta

      3 months 2 weeks ago
      Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will be functional soon. Looking forward to playing with this. #LLMs #ChatGPT More to come. @RheumNow https://t.co/mGXG6A85Hx
      Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024
      We need these biomarkers to come in mainstream clinical

      Bella Mehta bella_mehta

      3 months 2 weeks ago
      Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024 We need these biomarkers to come in mainstream clinical practice if they work better than proteinuria. @RheumNow https://t.co/i7aeBx6qRR